This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Nordoy T, Husebekk A, Aaberge IS et al. Humoral immunity to viral and bacterial antigens in lymphoma patients 4–10 years after high-dose therapy with ABMT. Serological responses to revaccination according to EBMT guidelines Bone Marrow Transplant 2001 28: 681 687
Bass JW, Halstead SB, Fischer GW et al. Oral poliovaccine: effect of booster vaccination one to 14 years after primary series JAMA 1978 239: 2252 2255
Franck S, Allwinn R, Rabenau HF, Doerr HW . Epidemiological analysis of immunity to poliovirus after termination of era of vaccination with OPV in Germany. An analysis of the German Association Against Viral Diseases (DVV) Zentralbl Bakteriol 1999 289: 475 481
Schorpe M . Plans to eradicate polio hit by virus outbreak in Bulgaria Nature 2001 411: 405
Hall AJ . Polio eradication as 2000 approaches Br Med J 1992 305: 69 70
Yoshida H, Horie H, Matsuura K, Mityamura T . Characterisation of vaccine-derived polioviruses isolated from sewage and river water in Japan Lancet 2000 356: 1461 1463
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Arya, S. Lymphoma patients undergoing high-dose therapy and ABMT, and EBMJ guidelines. Bone Marrow Transplant 29, 941 (2002). https://doi.org/10.1038/sj.bmt.1703559
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703559